The clearest approved use in this catalog: prescription hCG

Human chorionic gonadotropin, or hCG, is a glycoprotein hormone rather than a peptide. Current U.S. labeling includes selected cases of hypogonadotropic hypogonadism in males, meaning low gonadal function caused by insufficient pituitary signaling. That is a specific diagnosis and prescription indication—not a general testosterone, fertility, physique, or anti-aging claim.

The same labeling states that hCG has not been demonstrated to improve obesity treatment beyond calorie restriction. A research-vial listing also cannot be assumed to be equivalent to an FDA-regulated prescription product with an approved label.

Kisspeptin: meaningful human signals, but still experimental

Kisspeptin is an important reproductive signal. Small human studies now range from short laboratory observations to a 2026 randomized, single-blind, placebo-controlled study that recruited 15 healthy men and tested continuous administration for five days or daily eight-hour administration for 12 days. The 12-day schedule sustained increases in gonadotropins, while a separate 2023 randomized crossover trial in 32 men with hypoactive sexual desire disorder found short-term changes in sexual brain processing, penile tumescence, and some behavioral measures.

Those studies are scientifically useful but still do not establish routine treatment. The 2026 study measured reproductive hormones in healthy volunteers, used small groups across three study parts, and lasted no more than 12 days. It did not establish clinical effectiveness, long-term safety, or equivalence to a customer-facing research vial. Kisspeptin is not FDA approved for male low desire, hypogonadism, or infertility.

Sexual-health claims require product-specific evidence

Bremelanotide is often marketed by research vendors as PT-141. The approved prescription product Vyleesi has a narrow indication for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its labeling explicitly says it is not indicated for men and is not intended to enhance sexual performance.

That does not prove bremelanotide has no research relevance in men; it means a vendor vial cannot borrow the approval or dosing assumptions of a different regulated product. Claims about erectile function, desire, or performance need evidence for the exact ingredient, formulation, population, and outcome.

Metabolism and body composition are not men-only indications

Prescription products containing semaglutide or tirzepatide have substantial human evidence for specific metabolic indications in eligible adults. Their benefits and risks are not uniquely male, and they should not be repackaged as a men’s-health shortcut. Retatrutide remains investigational, and tesamorelin has a narrow approved use for excess abdominal fat in adults with HIV-associated lipodystrophy—not general weight loss or bodybuilding.

CJC-1295, ipamorelin, sermorelin, BPC-157, TB-500, MOTS-c, and popular blends are frequently promoted around muscle, recovery, energy, sleep, or aging. Current evidence does not establish a broadly safe or effective men’s-health program for research-vial versions of these compounds.

A practical way to read a men’s-health claim

First ask whether the exact product is FDA approved for the stated male condition. Then check whether the evidence measured a clinical outcome or only a short-lived hormone or imaging response, how many men participated, how long they were followed, and whether the tested formulation matches the product being discussed.

• Approved but narrow: prescription hCG for selected diagnosed male conditions.
• Human proof-of-concept research: kisspeptin for reproductive signaling and low sexual desire.
• Approved for other populations or purposes: bremelanotide, semaglutide, tirzepatide, and tesamorelin under their specific labels.
• Insufficient evidence for a general men’s-health treatment claim: most other research peptides and blends in the catalog.